Form 4: Karyopharm CEO Awarded 114,285 Restricted Stock Units

Karyopharm Therapeutics Inc. President and CEO, Richard A. Paulson, was awarded 114,285 restricted stock units under the company's 2022 Equity Incentive Plan.

Summary

• Richard A. Paulson, President and CEO, and a Director of Karyopharm Therapeutics Inc. (KPTI), was awarded 114,285 restricted stock units (RSUs).
• The transaction date for this award was October 15, 2025.
• These RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis.
• The RSUs were granted pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended.
• The RSUs will vest 100% on December 31, 2026.
• Following this transaction, Richard A. Paulson beneficially owns 198,331 shares of common stock.

Sentiment

Score: 7

Explanation: The award of restricted stock units to the CEO is generally a positive signal, indicating management alignment with shareholder interests and a commitment to long-term performance. It's a routine compensation event, not a significant new development, hence a moderate positive score.

Positives

• The award of restricted stock units aligns the interests of the President and CEO with those of shareholders, as the value of the award is tied to the company's stock performance.
• Equity awards are a common mechanism for executive retention and motivation, encouraging long-term commitment to the company's success.

Future Outlook

The awarded Restricted Stock Units are scheduled to vest 100% on December 31, 2026, indicating a future increase in Richard A. Paulson's direct beneficial ownership of Karyopharm Therapeutics Inc. common stock.

Industry Context

The award of restricted stock units to a President and CEO is a standard practice in the biotechnology and pharmaceutical industry for executive compensation, aiming to incentivize long-term performance and align management interests with shareholder value creation.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a component of executive compensation is a widely adopted practice across various industries, including biotechnology, aligning with common corporate governance principles.
• The vesting schedule, with a 100% vest on a future date, is typical for such awards, designed to encourage executive retention and sustained performance over a defined period.

Stakeholder Impact

• Shareholders: The RSU award aligns the CEO's financial interests with shareholder value, potentially leading to more focused long-term strategic decisions.
• Employees: Executive compensation practices can influence overall company morale and compensation structures, though this specific filing has no direct impact on general employees.

Next Steps

• The Restricted Stock Units will vest on December 31, 2026, at which point they will convert into Karyopharm Therapeutics Inc. common stock.

Key Dates

Keywords

Karyopharm Therapeutics, KPTI, Restricted Stock Units, RSU, Executive Compensation, Insider Transaction, Equity Incentive Plan, Beneficial Ownership